Related references
Note: Only part of the references are listed.Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry
Nancy L. Bartlett et al.
LEUKEMIA & LYMPHOMA (2017)
A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R) SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA (SALCL) OR R/R HODGKIN LYMPHOMA (HL)
F. Locatelli et al.
HEMATOLOGICAL ONCOLOGY (2017)
Phase 2 trial of brentuximab vedotin and gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma (HL): A Children's Oncology Group (COG) report.
Peter D. Cole et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
Anita Kumar et al.
BLOOD (2016)
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen et al.
BLOOD (2016)
Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program
Aurore Perrot et al.
HAEMATOLOGICA (2016)
Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program
Aurore Perrot et al.
HAEMATOLOGICA (2016)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz et al.
LANCET (2015)
The immune system and aging: a review
Camil Castelo-Branco et al.
GYNECOLOGICAL ENDOCRINOLOGY (2014)
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
Anas Younes et al.
LANCET ONCOLOGY (2013)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study
Sharon M. Castellino et al.
BLOOD (2011)
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism
K. A. Blum et al.
ANNALS OF ONCOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical features and correlates of gemcitabine-associated lung injury - Findings from the RADAR project
SM Belknap et al.
CANCER (2006)
Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin:: A report of the German Hodgkin's lymphoma Study Group
H Bredenfeld et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease
JW Friedberg et al.
CANCER (2003)
Share Paper
